UnitedHealth Group 面临褒贬不一的评论，但看到内部人士买入，维持“适度买入”评级。 UnitedHealth Group faces mixed reviews but sees insider buying, maintaining a "Moderate Buy" rating.

美国医疗集团的股票在最近几个季度的机构持有和分析师评级略有下降. UnitedHealth Group's stock saw a slight decrease in institutional holdings and mixed analyst ratings in recent quarters. 尽管收入和收入少了一点,但该公司保持强劲的市场地位,具有“机动购买”共识评级,目标价格为439.17美元。 Despite a minor miss on earnings and revenue, the company maintains a strong market position with a "Moderate Buy" consensus rating and a target price of $439.17. 内幕人士一直是积极的买家,首席执行官斯蒂芬·J·亨斯利明显增加了他的股权。 Insiders have been active buyers, with CEO Stephen J. Hemsley notably increasing his stake. 该公司通过四个部分运作:联合保健、 Optum Health、Optum Insight 和 Optum Rx。 The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx.